WO2008109532A8 - Nucleic acid compounds for inhibiting fas gene expression and uses thereof - Google Patents

Nucleic acid compounds for inhibiting fas gene expression and uses thereof Download PDF

Info

Publication number
WO2008109532A8
WO2008109532A8 PCT/US2008/055676 US2008055676W WO2008109532A8 WO 2008109532 A8 WO2008109532 A8 WO 2008109532A8 US 2008055676 W US2008055676 W US 2008055676W WO 2008109532 A8 WO2008109532 A8 WO 2008109532A8
Authority
WO
Grant status
Application
Patent type
Prior art keywords
nucleic acid
fas
gene expression
fas gene
uses
Prior art date
Application number
PCT/US2008/055676
Other languages
French (fr)
Other versions
WO2008109532A3 (en )
WO2008109532A4 (en )
WO2008109532A2 (en )
Inventor
Mohammad Ahmadian
James Mcswiggen
Steven C Quay
Narendra K Vaish
Original Assignee
Mohammad Ahmadian
James Mcswiggen
Mdrna Inc
Steven C Quay
Narendra K Vaish
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed

Abstract

The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing FAS gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a FAS mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a FAS gene in a cell or in a subject to treat a FAS-related disease.
PCT/US2008/055676 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting fas gene expression and uses thereof WO2008109532A8 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US93494007 true 2007-03-02 2007-03-02
US60/934,940 2007-03-02
US93493007 true 2007-03-16 2007-03-16
US60/934,930 2007-03-16
US1413907 true 2007-12-17 2007-12-17
US61/014,139 2007-12-17

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12552082 US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US13327545 US20130011922A1 (en) 2007-03-02 2011-12-15 Nucleic acid compounds for inhibiting gene expression and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055550 Continuation-In-Part WO2008109469A4 (en) 2007-03-02 2008-02-29 Nucleic acid compounds for inhibiting pcna gene expression and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2008/055368 Continuation-In-Part WO2008109366A4 (en) 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof
US12552082 Continuation-In-Part US20100105134A1 (en) 2007-03-01 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
AU2009212920A Division AU2009212920A8 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof

Publications (4)

Publication Number Publication Date
WO2008109532A2 true WO2008109532A2 (en) 2008-09-12
WO2008109532A3 true WO2008109532A3 (en) 2008-11-27
WO2008109532A4 true WO2008109532A4 (en) 2009-01-15
WO2008109532A8 true true WO2008109532A8 (en) 2009-08-06

Family

ID=39731271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055676 WO2008109532A8 (en) 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting fas gene expression and uses thereof

Country Status (1)

Country Link
WO (1) WO2008109532A8 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013886A3 (en) * 2002-10-30 2006-03-23 Blood Res Center Methods for treating and preventing apoptosis-related diseases using rna interfering agents
US20050136437A1 (en) * 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
WO2005042719A3 (en) * 2003-10-30 2007-02-22 Cbr Inst For Biomed Res Inc Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents
EP1942943A2 (en) * 2005-11-04 2008-07-16 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna

Also Published As

Publication number Publication date Type
WO2008109532A3 (en) 2008-11-27 application
WO2008109532A4 (en) 2009-01-15 application
WO2008109532A2 (en) 2008-09-12 application

Similar Documents

Publication Publication Date Title
Nykänen et al. ATP requirements and small interfering RNA structure in the RNA interference pathway
Yates et al. The long and short of microRNA
Gomez et al. Telomerase downregulation induced by the G‐quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing
Guo et al. CELL-SELEX: Novel perspectives of aptamer-based therapeutics
Shah et al. MicroRNAs as therapeutic targets in human cancers
WO2009078470A1 (en) Complex of polysaccharide and double-stranded rna
Brunner et al. Cell‐Penetrating and Neurotargeting Dendritic siRNA Nanostructures
Snead et al. Biogenesis and function of endogenous and exogenous siRNAs
Hu et al. Signals from noncoding RNAs: unconventional roles for conventional pol III transcripts
WO2007109330A3 (en) S1p receptor modulating compounds
WO2006083800A3 (en) Nucleic acid silencing of huntington's disease gene
WO2004015107A3 (en) Further novel forms of interfering rna molecules
WO2004007718A3 (en) Rna-interference by single-stranded rna molecules
Agarwal et al. Furan based cyclic homo-oligopeptides bind G-quadruplex selectively and repress c-MYC transcription
WO2008073920A3 (en) Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008091934A3 (en) Fructose 1, 6 bisphosphate - a novel anticonvulsant drug
WO2005071080A3 (en) Modulation of glucocorticoid receptor expression
WO2010013815A1 (en) Composition for inhibiting expression of target gene
WO2005028628A3 (en) Modulation of eif4e expression
Nishiyama et al. pH-Dependence of the thermal stability of metallo-DNA duplexes containing ligand-type 5-hydroxyuracil nucleobases
WO2005105995A3 (en) RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2004046160A8 (en) Amino-lna, thio-lna and alpha-l-oxy-ln
Pelucchi et al. A versatile tool for stable inhibition of microRNA activity
Hasler et al. An argonaute protein directs nuclear Xrn2 function
WO2011005860A3 (en) 5' phosphate mimics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731264

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 08731264

Country of ref document: EP

Kind code of ref document: A2